Author(s)

Maria Rosaria Valerio¹, Chiara Ancona¹, Antonella Marchese², Vittorio Gebbia^2*

¹Medical Oncology Unit, Department of Oncology, University of Palermo, Palermo, Italy.
²Medical Oncology Unit, La Maddalena Clinic for Cancer, University of Palermo, Palermo, Italy.

Background: Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily pretreated patients is still largely unclear. In the last decade, nab-paclitaxel has shown significant activity and good toxicity profile in metastatic breast cancer. Case Presentation: We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral capecitabine and lapatinib. Clinical and radiological staging showed progression at bone, skin and soft-tissue. The patient received weekly nab-paclitaxel plus trastuzumab. Massive objective response was clinically and PET documented which lasted 8 months. Tolerance to treatment was fairly good as well as cardiac safety. Conclusion: To the best of our knowledge, this is the first reported case of efficacy of nab-paclitaxel in combination with trastuzumab as fifth-line of treatment in a patient with metastatic HER-2 positive breast cancer.

Nab-Paclitaxel, Trastuzumab, HER-2, Metastasis, Breast Cancer

Valerio, M. , Ancona, C. , Marchese, A. and Gebbia, V. (2017) Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient. Journal of Cancer Therapy, 8, 933-940. doi: 10.4236/jct.2017.811082.